Literature DB >> 22983185

Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus.

Ernesto Marcos1, Lázaro Gil, Laura Lazo, Alienys Izquierdo, Enma Brown, Edith Suzarte, Iris Valdés, Angélica García, Lissandra Méndez, María G Guzmán, Gerardo Guillén, Lisset Hermida.   

Abstract

It was previously reported that DIIIC-2 (a fusion protein composed of domain III of the envelope protein and the capsid protein from dengue 2 virus), as an aggregate antigen from a partially purified preparation, induced a functional protective immune response against dengue 2 virus in the mouse encephalitis model. In the present work, a purification procedure was developed for DIIIC-2, and soluble and aggregated fractions of the purified protein were characterized and evaluated in mice. The purification process rendered a protein preparation of 91 % purity, and the remaining 9 % consisted of fragments and aggregates of the same recombinant protein. After the in vitro aggregation process, upon addition of oligodeoxynucleotides, 80 % of the protein formed aggregates, whereas 20 % remained as soluble protein. An immunological evaluation revealed the proper immunogenicity of the aggregated purified protein in terms of induction of antiviral and neutralizing antibodies, cell-mediated immunity and protection upon dengue 2 virus challenge in the mouse encephalitis model. Based on these results, we can assert that the purified protein DIIIC-2 is functional and could be used for further scalable steps and preclinical studies in non-human primates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983185     DOI: 10.1007/s00705-012-1471-z

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  6 in total

1.  Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Authors:  Julia C Frei; Ariel S Wirchnianski; Jennifer Govero; Olivia Vergnolle; Kimberly A Dowd; Theodore C Pierson; Margaret Kielian; Mark E Girvin; Michael S Diamond; Jonathan R Lai
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

2.  The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.

Authors:  Lázaro Gil; Ernesto Marcos; Alienys Izquierdo; Laura Lazo; Iris Valdés; Peris Ambala; Lucy Ochola; Rikoi Hitler; Edith Suzarte; Mayling Álvarez; Prisilla Kimiti; James Ndung'u; Thomas Kariuki; María Guadalupe Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Immunol Cell Biol       Date:  2014-09-02       Impact factor: 5.126

3.  Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.

Authors:  Roland Züst; Ying-Xiu Toh; Iris Valdés; Daniela Cerny; Julia Heinrich; Lisset Hermida; Ernesto Marcos; Gerardo Guillén; Ulrich Kalinke; Pei-Yong Shi; Katja Fink
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

Review 4.  Understanding the dengue viruses and progress towards their control.

Authors:  Rosmari Rodriguez-Roche; Ernest A Gould
Journal:  Biomed Res Int       Date:  2013-07-09       Impact factor: 3.411

5.  A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies.

Authors:  Anthony J S Chua; Cyrielle Vituret; Melvin L C Tan; Gaëlle Gonzalez; Pierre Boulanger; Mah-Lee Ng; Saw-See Hong
Journal:  Virol J       Date:  2013-04-24       Impact factor: 4.099

6.  Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.

Authors:  Hui Zhao; Tao Jiang; Xi-Zhen Zhou; Yong-Qiang Deng; Xiao-Feng Li; Shui-Ping Chen; Shun-Ya Zhu; Xi Zhou; E-De Qin; Cheng-Feng Qin
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.